Moayyeri, A.
Warden, J.
Han, S.
Suh, H.S.
Pinedo-Villanueva, R.
Harvey, N.C.
Curtis, J.R.
Silverman, S.
Multani, J.K.
Yeh, E.J. http://orcid.org/0000-0002-9357-9626
Article History
Received: 21 February 2023
Accepted: 21 August 2023
First Online: 31 August 2023
Declarations
:
: The Sax Institute’s 45 and Up Study has ethical approval from the University of New South Wales Human Research Ethics Committee. Ethics approval for this project was provided by the NSW Population Health Services Research Ethics Committee (approval 2019/ETH00118). Due to the nature of secondary data, formal consent was not required for the Germany, South Korea, Spain, and US studies.
: All 45 and Up Study participants provided informed consent for the use of their data in study-approved projects. Informed consent was not applicable to the Germany, South Korea, Spain, and US studies.
: Alireza Moayyeri is an employee of UCB Pharma and holds UCB stocks. Joshua Warden is an employee of UCB Pharma with no UCB stock. Sola Han has no conflict of interest. Hae Sun Suh received a research grant from Amgen Inc. to conduct the South Korean study of this work at Kyung Hee University. Rafael Pinedo-Villanueva has received research funding from the UK NIHR, the International Osteoporosis Foundation, Kyowa Kirin Services, Fondation privée des HUG (Geneva, Switzerland), Amgen Inc., and the Royal Osteoporosis Society and lecture fees and/or consulting honoraria from Amgen Inc., UCB, Kyowa Kirin Services, Astellas, the International Osteoporosis Foundation, and Mereo BioPharma. Nicholas C. Harvey reports personal fees, consultancy, lecture fees, and honoraria from Alliance for Better Bone Health, Amgen Inc., MSD, Eli Lilly, UCB, Kyowa Kirin, Servier, Shire, Consilient Healthcare, and Internis Pharmaceuticals, outside the submitted work. Jeffrey R. Curtis reports consulting fees and research grants from Amgen Inc. Stuart Silverman received research grants, consulting fees, and honoraria from Amgen Inc., and honoraria from Radius Health. Jasjit K. Multani is an employee of IQVIA, which was contracted by Amgen Inc. and UCB to conduct the Australia, Spain, and US studies of this work. Eric J. Yeh is an employee of Amgen Inc. and holds Amgen stock.